Bausch + Lomb Corporation (BLCO)
NYSE: BLCO · Real-Time Price · USD
16.23
-0.50 (-2.99%)
At close: Jul 10, 2026, 4:00 PM EDT
16.25
+0.02 (0.12%)
After-hours: Jul 10, 2026, 7:00 PM EDT
Bausch + Lomb Revenue
Bausch + Lomb had revenue of $1.24B in the quarter ending March 31, 2026, with 9.41% growth. This brings the company's revenue in the last twelve months to $5.89B, up 8.39% year-over-year. In the year 2025, Bausch + Lomb had annual revenue of $5.10B with 6.47% growth.
Revenue (ttm)
$5.89B
Revenue Growth
+8.39%
P/S Ratio
1.11
Revenue / Employee
$400,615
Employees
13,000
Market Cap
5.79B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.10B | 310.00M | 6.47% |
| Dec 31, 2024 | 4.79B | 645.00M | 15.56% |
| Dec 31, 2023 | 4.15B | 378.00M | 10.03% |
| Dec 31, 2022 | 3.77B | 3.00M | 0.08% |
| Dec 31, 2021 | 3.77B | 353.00M | 10.35% |
| Dec 31, 2020 | 3.41B | -366.00M | -9.69% |
| Dec 31, 2019 | 3.78B | 113.00M | 3.08% |
| Dec 31, 2018 | 3.67B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Baxter International | 11.32B |
| Avantor | 6.55B |
| AptarGroup | 3.87B |
| MiniMed Group | 3.10B |
| Envista Holdings | 2.81B |
| ICU Medical | 2.16B |
| Teleflex | 2.13B |
| Merit Medical Systems | 1.54B |
BLCO News
- 1 day ago - Bausch + Lomb says Phase 2 study of BL1107 did not achieve primary endpoint - TheFly
- 1 day ago - Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate - Business Wire
- 1 day ago - Bausch + Lomb introduces Orphia AI-powered digital health platform - TheFly
- 1 day ago - Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care - Business Wire
- 2 days ago - Bausch + Lomb price target raised to $21 from $19 at Citi - TheFly
- 4 days ago - Bausch + Lomb price target raised to $17 from $16 at Evercore ISI - TheFly
- 4 days ago - Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29 - Business Wire
- 9 days ago - Bausch + Lomb announces new findings from third State of Dry Eye survey - TheFly